Risk Factors Update Summary
- The company is substantially dependent on the success of SLK, with ongoing and anticipated clinical trials.
- The company entered into an agreement with RCT and MHKDG, effective June 1, 2023, for SLK development.
- The company announced full 24-week data from the global Phase 2 MIRA trial in October 2023.
- The company expects a primary endpoint readout in mid-2023 for the ARGO trial.
- The company faces substantial competition from major pharmaceutical companies in developing SLK.
- The company may encounter delays in clinical trials, impacting business, financial condition, and results.
- The company's ability to execute its business plan relies on uninterrupted performance of IT systems.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1821586&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.